Aplenzin (bupropion hydrobromide) extended-release tablets have been made available by sanofi-aventis for the treatment of major depressive disorder (MDD) for adults ≥18 years of age. Aplenzin’s hydrobromide salt extended-release formulation of bupropion offers prescribers and patients the convenience of single tablet, once-daily dosing at all doses. Aplenzin was approved by the FDA in April 2008.
Aplenzin is available as 348mg and 522mg dosage strengths.
For more information call (800) 633-1610 or visit www.aplenzin.com.